MicuRx(SH:688373) Xin Lang Cai Jing·2025-10-14 01:35Core Viewpoint - On October 13, 2023, Amgen Pharmaceuticals experienced a decline of 3.86% in stock price, with a trading volume of 196 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On the same day, Amgen Pharmaceuticals had a financing buy-in amount of 12.67 million yuan and a financing repayment of 15.68 million yuan, resulting in a net financing outflow of 3.01 million yuan [1]. - As of October 13, the total financing and securities balance for Amgen Pharmaceuticals was 82.06 million yuan, which represents 1.90% of its circulating market value and is above the 80th percentile level over the past year, indicating a high financing balance [1]. - The company had no short-selling activity on October 13, with a short-selling balance of 0.00 yuan, also reflecting a high percentile level over the past year [1]. Company Profile - Amgen Pharmaceuticals, established on August 7, 2012, and listed on August 5, 2022, is located in the China (Shanghai) Free Trade Zone. The company focuses on innovative drugs for treating infectious diseases and holds global intellectual property rights [1]. - The main business revenue is derived entirely from the sales of Kantrizole tablets, accounting for 100% of the company's revenue [1]. Shareholder Information - As of June 30, 2025, Amgen Pharmaceuticals had 14,400 shareholders, an increase of 14.23% from the previous period, while the average circulating shares per person decreased by 12.45% to 25,342 shares [2]. - For the first half of 2025, the company reported a revenue of 66.97 million yuan, reflecting a year-on-year growth of 10.26%, but incurred a net loss of 139 million yuan, which is a 31.11% increase in losses compared to the previous year [2]. - Notably, as of June 30, 2025, the fund "Huitianfu Medical Service Flexible Allocation Mixed A" exited the list of the top ten circulating shareholders [2].